Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $516.22 million. The Firm is focused on the development and commercialization of pharmaceutical products. It has a 26.15 P/E ratio. The Company’s primary focus areas are gastroenterology, ophthalmology and oncology-related disorders.
Leonard Steinberg, SVP – Legal/Reg/Gov & Corp Sec. of Alaska Communications Systems Group Inc, in an insider selling made a sale of 2,000 shares whose value is estimated to be $3,720 at average stock price of $1.9. He also sold 4,000 shares worth $6,980 USD in the last month. Right now, Leonard Steinberg has in hand 502,762 shares or precisely 0.99% of Alaska Communications Systems Group Inc’s market cap (share price times the number of shares outstanding).
Since January 12, 2017, it had 0 insider buys, and 5 insider sales for $15,677 activity. On Thursday, January 12 STEINBERG LEONARD sold $3,440 worth of Alaska Communications Systems Group Inc (NASDAQ:ALSK) or 2,000 shares.
Investors sentiment increased to 2.08 in 2016 Q4. Its up 1.13, from 0.95 in 2016Q3. It increased, as 2 investors sold Alaska Communications Systems Group Inc shares while 10 reduced holdings. 6 funds opened positions while 19 raised stakes. 19.97 million shares or 7.46% more from 18.58 million shares in 2016Q3 were reported. Blackrock Investment Mgmt Limited Liability Company has invested 0% in Alaska Communications Systems Group Inc (NASDAQ:ALSK). Creative Planning holds 2,000 shares. Missouri-based Eidelman Virant Cap has invested 0.3% in Alaska Communications Systems Group Inc (NASDAQ:ALSK). Sequoia Fincl Advsr Limited Liability Corporation reported 12,500 shares or 0% of all its holdings. Winslow Evans & Crocker has 0% invested in Alaska Communications Systems Group Inc (NASDAQ:ALSK) for 200 shares. Susquehanna Gp Ltd Liability Partnership reported 16,032 shares stake. Kcg, a New Jersey-based fund reported 48,306 shares. Vanguard Grp Inc holds 2.53 million shares or 0% of its portfolio. Moreover, Comml Bank Of America Corp De has 0% invested in Alaska Communications Systems Group Inc (NASDAQ:ALSK). Spark Invest Mgmt Limited Co holds 0.01% in Alaska Communications Systems Group Inc (NASDAQ:ALSK) or 88,600 shares. Blackrock Institutional Tru Na holds 0% or 1.68 million shares. Fifth Third Bank & Trust holds 0% or 665 shares in its portfolio. Tower Research Capital Lc (Trc) has 8,116 shares for 0% of their portfolio. Jpmorgan Chase And reported 0% in Alaska Communications Systems Group Inc (NASDAQ:ALSK). Kornitzer Capital Mgmt Ks stated it has 65,000 shares.
Analysts await Alaska Communications Systems Group Inc (NASDAQ:ALSK) to report earnings on May, 8.
The stock decreased 2.12% or $0.04 on April 7, reaching $1.85. About shares traded. Alaska Communications Systems Group Inc (NASDAQ:ALSK) has risen 8.82% since September 1, 2016 and is uptrending. It has outperformed by 0.32% the S&P500.
Alaska Communications Systems Group, Inc. is a fiber broadband and managed information technology services provider. The company has market cap of $94.08 million. The Firm is focused primarily on business and wholesale clients in and out of Alaska. It has a 40.56 P/E ratio. The Firm also provides telecommunication services to clients across Alaska.
Krensavage Asset Management Llc holds 9.05% of its portfolio in Sucampo Pharmaceuticals, Inc. for 1.86 million shares. Redwood Investments Llc owns 603,814 shares or 0.74% of their US portfolio. Moreover, Clark Estates Inc Ny has 0.57% invested in the company for 250,000 shares. The California-based Malaga Cove Capital Llc has invested 0.36% in the stock. Ativo Capital Management Llc, a Illinois-based fund reported 109,023 shares.
Ratings analysis reveals 67% of Sucampo Pharma’s analysts are positive. Out of 9 Wall Street analysts rating Sucampo Pharma, 6 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $14 while the high is $31. The stock’s average target of $22.75 is 111.63% above today’s ($10.75) share price. SCMP was included in 22 notes of analysts from August 6, 2015. TH Capital reinitiated the stock with “Buy” rating in Thursday, October 29 report. Roth Capital reinitiated the shares of SCMP in report on Thursday, October 29 with “Buy” rating. The stock has “Hold” rating by Jefferies on Wednesday, March 9. As per Thursday, September 3, the company rating was initiated by Leerink Swann. The firm has “Neutral” rating by Mizuho given on Thursday, August 4. The firm earned “Buy” rating on Tuesday, November 15 by Maxim Group. The rating was maintained by Mizuho on Friday, November 13 with “Neutral”. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) earned “Hold” rating by Jefferies on Friday, November 20. The rating was initiated by UBS with “Buy” on Tuesday, February 9. The company was initiated on Monday, August 24 by H.C. Wainwright.
Analysts await Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report earnings on May, 3. They expect $0.27 EPS, up 28.57% or $0.06 from last year’s $0.21 per share. SCMP’s profit will be $12.97M for 9.95 P/E if the $0.27 EPS becomes a reality. After $0.68 actual EPS reported by Sucampo Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -60.29% negative EPS growth.
